NCT00117065已完成4 期
Study of Transplant Related Anemia Treated With Aranesp® (STRATA)
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Amgen
- 主要终点
- Hemoglobin values
研究概览
简要总结
The purpose of this study was to evaluate Aranesp® administered subcutaneously (SC) to maintain hemoglobin (Hb) levels in renal transplant recipients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who are greater than 6 months post-renal transplant (living or cadaveric) - Using adequate contraceptive precaution, if of childbearing potential - Available for follow-up assessments and dosing visits - Hb concentration less than 11.0 g/dL within 3 months of screening and a hemoglobin concentration less than 11.0 during the screening period
排除标准
- •Expected to initiate dialysis or transplantation or be scheduled for a kidney transplant within 6 months of study start, or have less than 1 year life expectancy - Systemic hematologic disease, myeloma, hemolytic anemia, or malignancy (excluding basal cell carcinoma) - Active systemic or chronic infection - Uncontrolled hypertension defined as diastolic blood pressure greater than 110 mm Hg on 2 separate occasions during the 2 weeks prior to screening - Known hypersensitivity to Aranesp® or any of the product's excipients - Disorders that compromise the ability of the subject to give written informed consent and/or to comply with study procedures - Use of any erythropoietic protein or androgen therapy within the 12 weeks prior to screening - Females who are pregnant or breast-feeding - Currently enrolled in or received treatment in an investigational drug/device trial within the past 30 days - Have previously been enrolled in this study - Recent history (within 12 weeks prior to screening) of severe cardiovascular events, grand mal seizure, dialysis or major surgery - Have received a red blood cell transfusion(s) within 8 weeks prior to screening, or currently have active bleeding
结局指标
主要结局
Hemoglobin values
次要结局
- SF-36 summary and individual domain scores at week 24
研究者
相似试验
已完成
4 期
STAAR-3 Clinical StudyChronic Renal InsufficiencyPre-dialysisPre-ESRDChronic Kidney DiseaseKidney DiseaseNCT00369733Amgen443
已完成
不适用
Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney DiseaseAnemia of Chronic Kidney DiseaseNCT03427801Chinese University of Hong Kong78
已完成
2 期
Study of Aranesp to Treat Anemia in Prostate Cancer Patients.Prostate CancerAnemiaNCT00245895University of Washington20
已完成
4 期
Effects of Anemia Correction on Vascular and Monocyte Function in Renal Transplant RecipientsKidney TransplantationAnemiaNCT00204334University Hospital Muenster60
已完成
2 期
Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)AnemiaNCT00286182Mathew S. Maurer56